Newsfeeds - Spark Newswire

1 minute read

Castle Biosciences Announced Preliminary FY 2022 Total Revenue Expected To Meet Or Exceed Top End Of Guided Range Of $132M–137M vs 135.47M Est

Today, 11:49 AM

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced certain unaudited preliminary performance results for the fourth quarter and full-year ended Dec. 31, 2022. 2022 total revenue expected to meet or exceed top end of guided range of $132–137 million

CSTL

1 minute read

Scotiabank Initiates Coverage On Castle Biosciences with Sector Outperform Rating, Announces Price Target of $54

By Benzinga Newsdesk

Today, 11:49 AM

Scotiabank analyst Sung Ji Nam initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Sector Outperform rating and announces Price Target of $54.

CSTL

1 minute read

News

Castle Biosciences Receives Accreditation From The College Of American Pathologists For Its Pittsburgh Clinical Laboratory

By Benzinga Newsdesk

Today, 11:49 AM

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has

CSTL

2 minute read

This Analyst With 90% Accuracy Rate Raises PT On Chesapeake Energy; Here Are 5 Stock Picks For Last Week From Benzinga’s Most Accurate Analysts

By Lisa Levin

Today, 11:49 AM

Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst's opinion to trust.

CHK

2 minute read

Castle Biosciences Announces Results From A Randomized Controlled Trial Show That TissueCypher Barrett’s Esophagus Test Results Can Significantly Improve The Accuracy Of Risk Assessments And Adherence To Guideline-recommended Patient Management

By Benzinga Newsdesk

Today, 11:49 AM

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a randomized controlled trial (RCT) showing that use of TissueCypher®

CSTL

2 minute read

Castle Biosciences To Present Data Supporting The Clinical Value Of Its Suite Of Skin Cancer Tests Through Multiple Oral Presentations At The 2022 American Society For Dermatologic Surgery Annual Meeting

By Benzinga Newsdesk

Today, 11:49 AM

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, is presenting data highlighting its portfolio of skin cancer gene expression profile (GEP) tests at the

CSTL

1 minute read

Castle Biosciences Sees FY Revenue $255M-$330M

By Michael Horton

Today, 11:49 AM

-Reuters

CSTL

2 minute read

Earnings

Castle Biosciences’s Return On Capital Employed Overview

By Benzinga Insights

Today, 11:49 AM

According to data from Benzinga Pro, during Q2, Castle Biosciences's (NASDAQ:CSTL) reported sales totaled $34.84 million. Despite a 93.31% increase in earnings, the company posted a loss of $1.65 million.

CSTL

1 minute read

Earnings

Castle Biosciences: Q2 Earnings Insights

By Benzinga Insights

Today, 11:49 AM

Castle Biosciences (NASDAQ:CSTL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

CSTL

5 minute read

Mosaic Tumbles Around 10%, Here’s 71 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:49 AM

Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown offering.

ADN